Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Supernus Pharmaceuticals has received a consensus rating of “Moderate Buy” from five brokerages, with a 12-month target price averaging $51.50.
• Insider trading activity has been notable, with significant sales by senior executives, including a sale of 14,000 shares by SVP Frank Mottola, marking a 47.46% decrease in his holdings.
• The company's stock rose 0.8%, trading at $48.35, reflecting increasing investor interest and activity.

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five brokerages that are presently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $51.50.

A number of equities analysts recently issued reports on SUPN shares. Piper Sandler upped their price target on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the stock a "neutral" rating in a research note on Friday, August 29th. Wall Street Zen raised shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Cantor Fitzgerald upped their price target on shares of Supernus Pharmaceuticals from $46.00 to $63.00 and gave the company an "overweight" rating in a research report on Tuesday. Weiss Ratings reissued a "hold (c)" rating on shares of Supernus Pharmaceuticals in a report on Saturday, September 27th. Finally, Zacks Research raised shares of Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, September 17th.

Supernus Pharmaceuticals Stock Up 0.8%

Shares of NASDAQ:SUPN traded up $0.39 during midday trading on Friday, reaching $48.35. The company's stock had a trading volume of 939,438 shares, compared to its average volume of 645,347. The firm has a 50 day moving average of $43.23 and a 200-day moving average of $36.00. The firm has a market capitalization of $2.71 billion, a P/E ratio of 42.04 and a beta of 0.78. Supernus Pharmaceuticals has a 12-month low of $29.16 and a 12-month high of $49.66.

Insider Activity

In other news, SVP Frank Mottola sold 14,000 shares of the stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $44.51, for a total transaction of $623,140.00. Following the completion of the transaction, the senior vice president directly owned 15,496 shares in the company, valued at approximately $689,726.96. This represents a 47.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bethany Sensenig sold 5,369 shares of the stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $42.25, for a total value of $226,840.25. The disclosure for this sale can be found here. In the last ninety days, insiders sold 302,841 shares of company stock worth $13,361,449. 8.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of SUPN. Two Sigma Advisers LP lifted its position in Supernus Pharmaceuticals by 14.7% in the fourth quarter. Two Sigma Advisers LP now owns 7,800 shares of the specialty pharmaceutical company's stock worth $282,000 after buying an additional 1,000 shares during the last quarter. Principal Financial Group Inc. lifted its position in Supernus Pharmaceuticals by 3.2% in the first quarter. Principal Financial Group Inc. now owns 306,322 shares of the specialty pharmaceutical company's stock worth $10,032,000 after buying an additional 9,590 shares during the last quarter. SG Americas Securities LLC lifted its position in Supernus Pharmaceuticals by 63.6% in the first quarter. SG Americas Securities LLC now owns 17,671 shares of the specialty pharmaceutical company's stock worth $579,000 after buying an additional 6,867 shares during the last quarter. QRG Capital Management Inc. lifted its position in Supernus Pharmaceuticals by 5.5% in the first quarter. QRG Capital Management Inc. now owns 17,583 shares of the specialty pharmaceutical company's stock worth $576,000 after buying an additional 913 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in Supernus Pharmaceuticals by 4,005.4% in the first quarter. GAMMA Investing LLC now owns 43,230 shares of the specialty pharmaceutical company's stock worth $1,320,000 after buying an additional 42,177 shares during the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.